FMP
PolyPid Ltd.
PYPD
NASDAQ
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
3.17 USD
-0.0642 (-2.03%)
Overall Rating
Discounted Cash Flow
Return on Equity
Return on Assets
Debt to Equity
Price to Earnings
Price to Book
We are unable to load the data!
We are unable to load the data!